ZFuze is an anti-inflammatory, osseoconductive, load-bearing biomaterial, according to a Jan. 14 news release. It’s the first biomaterial of its kind approved by the FDA, and ZFuze has a 93.4% lumbar spinal fusion rate at six months.
The patent protects ZFuze’s Master File for another 17 years, CEO and founder Derrick Johns said in the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
